{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:03:40Z","timestamp":1787169820397,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Wild-type TP53 plays an important role in the regulation of immune response and systemic inflammation. In type 1 diabetes (T1D),\n                      <jats:italic>TP53<\/jats:italic>\n                      pathways are upregulated and an increased susceptibility to apoptosis is observed. We hypothesize that\n                      <jats:italic>TP53<\/jats:italic>\n                      codon 72 polymorphism could be associated with complications and comorbidities in patients with T1D. We have investigated the associations of the\n                      <jats:italic>TP53<\/jats:italic>\n                      codon 72 polymorphism with the T1D complications and comorbidities (retinopathy, nephropathy, hypertension, dyslipidemia, autoimmune thyroiditis, and celiac disease) in 350 patients. The key results of our approach are as follows: (1) In diabetic subjects, the Pro\/Pro genotype is associated with an increased risk of microvascular complications, dyslipidemia, and celiac disease; (2) the Arg\/Arg variant is associated with a decreased risk of autoimmune thyroiditis and celiac disease; (3) the Pro allele is associated with an increased risk of dyslipidemia, autoimmune thyroiditis, and celiac disease. Although further studies are required, our results for the first time indicate that the\n                      <jats:italic>TP53<\/jats:italic>\n                      codon 72 polymorphism could be considered a genetic marker to predict the increased susceptibility to some T1D complications and comorbidities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key messages<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            We analyzed the\n                            <jats:italic>TP53<\/jats:italic>\n                            codon 72 polymorphism in patients with T1D.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Pro\/Pro genotype is associated with an increased risk of microvascular complications, dyslipidemia, and celiac disease.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The Arg\/Arg variant is associated with a decreased risk of autoimmune thyroiditis and celiac disease.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The Pro allele is associated with an increased risk of dyslipidemia, autoimmune thyroiditis, and celiac disease.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00109-020-02035-1","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T12:05:31Z","timestamp":1611576331000},"page":"675-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Associations of TP53 codon 72 polymorphism with complications and comorbidities in patients with type 1 diabetes"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4084-0840","authenticated-orcid":false,"given":"Bartosz","family":"S\u0142omi\u0144ski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Skrzypkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ryba-Stanis\u0142awowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"My\u015bliwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Trzonkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"2035_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/15384101.2017.1412147","volume":"17","author":"AK Ashley","year":"2018","unstructured":"Ashley AK, Kemp CJ (2018) DNA-PK, ATM, and ATR: PIKKing on p53. Cell Cycle 17:275\u2013276","journal-title":"Cell Cycle"},{"key":"2035_CR2","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/nature07986","volume":"458","author":"DR Green","year":"2009","unstructured":"Green DR, Kroemer G (2009) Cytoplasmic functions of the tumour suppressor p53. Nature 458:1127\u20131130","journal-title":"Nature"},{"key":"2035_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/BF00787230","volume":"19","author":"RV Sionov","year":"1998","unstructured":"Sionov RV, Haupt Y (1998) Apoptosis by p53: mechanisms, regulation, and clinical implication. Springer Semin Immunopathol 19:345\u2013362","journal-title":"Springer Semin Immunopathol"},{"key":"2035_CR4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrc2715","volume":"9","author":"KH Vousden","year":"2009","unstructured":"Vousden KH, Ryan KM (2009) p53 and metabolism. Nat Rev Cancer 9:691\u2013700","journal-title":"Nat Rev Cancer"},{"key":"2035_CR5","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.celrep.2016.02.037","volume":"14","author":"CP Kung","year":"2016","unstructured":"Kung CP, Leu JI, Basu S, Khaku S, Anokye-Danso F, Liu Q, George DL, Ahima RS, Murphy ME (2016) The P72R polymorphism of p53 predisposes to obesity and metabolic dysfunction. Cell Rep 14:2413\u20132425","journal-title":"Cell Rep"},{"key":"2035_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1615\/CritRevImmunol.2014012193","volume":"34","author":"H Takatori","year":"2014","unstructured":"Takatori H, Kawashima H, Suzuki K, Nakajima H (2014) Role of p53 in systemic autoimmune diseases. Crit Rev Immunol 34:509\u2013516","journal-title":"Crit Rev Immunol"},{"key":"2035_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4161\/cc.7.2.5249","volume":"7","author":"SE Bojesen","year":"2008","unstructured":"Bojesen SE, Nordestgaard BG (2008) The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle 7:158\u2013163","journal-title":"Cell Cycle"},{"key":"2035_CR8","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1128\/MCB.19.2.1092","volume":"19","author":"M Thomas","year":"1999","unstructured":"Thomas M, Kalita A, Labrecque S, Pim D, Ban L (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092\u20131100","journal-title":"Mol Cell Biol"},{"key":"2035_CR9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1096\/fj.09-146001","volume":"24","author":"BS Jeong","year":"2010","unstructured":"Jeong BS, Hu W, Belyi V, Rabadan R, Levine AJ (2010) Differential levels of transcription of p53-regulated genes by the arginine\/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J 24:1347\u20131353","journal-title":"FASEB J"},{"key":"2035_CR10","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.2337\/dc10-S062","volume":"33","author":"American Diabetes Association","year":"2010","unstructured":"American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:S62\u2013S69","journal-title":"Diabetes Care"},{"key":"2035_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1542\/peds.114.S2.555","volume":"114","author":"National High Blood Pressure Program Working Group on High Blood Pressure in Children and Adolescents","year":"2004","unstructured":"National High Blood Pressure Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescent. Pediatrics 114:555\u2013576","journal-title":"Pediatrics"},{"key":"2035_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0161-6420(13)38013-0","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group (1991) Classification of diabetic retinopathy from fluorescein angiograms. Ophthalmology 98:807\u2013822","journal-title":"Ophthalmology"},{"key":"2035_CR13","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2215\/CJN.06460710","volume":"6","author":"JJ Fadrowski","year":"2011","unstructured":"Fadrowski JJ, Neu AM, Schwartz GJ, Furth SL (2011) Pediatric GFR estimating equations applied to adolescents in the general population. Clin J Am Soc Nephrol 6:1427\u20131435","journal-title":"Clin J Am Soc Nephrol"},{"key":"2035_CR14","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.2337\/diacare.26.7.2194","volume":"26","author":"American Diabetes Association","year":"2003","unstructured":"American Diabetes Association (2003) Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 26:2194\u20132197","journal-title":"Diabetes Care"},{"key":"2035_CR15","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.jpeds.2009.04.051","volume":"155","author":"S Cook","year":"2009","unstructured":"Cook S, Auinger P, Huang TT (2009) Growth curves for cardio-metabolic risk factors in children and adolescents. J Pediatr 155:S6\u2013S26","journal-title":"J Pediatr"},{"key":"2035_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/adc.65.8.909","volume":"65","author":"JA Walker-Smith","year":"1990","unstructured":"Walker-Smith JA, Guandalini S, Schmitz J, Shmerling DH, Visakorpi JK (1990) Revised criteria for diagnosis of coeliac disease. Arch Dis Child 65:909\u2013911 http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1792502\/?page=1","journal-title":"Arch Dis Child"},{"key":"2035_CR17","first-page":"1047","volume":"61","author":"J Slatosky","year":"2000","unstructured":"Slatosky J, Shipton B, Wahaba H (2000) Thyroiditis: differential diagnosis and management. Am Fam Physician 61:1047\u20131052 http:\/\/www.aafp.org\/afp\/2000\/0215\/p1047.html","journal-title":"Am Fam Physician"},{"key":"2035_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickison DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultra. Clin Chem 18:499\u2013502 http:\/\/clinchem.aaccjnls.org\/content\/18\/6\/499.long","journal-title":"Clin Chem"},{"key":"2035_CR19","doi-asserted-by":"publisher","first-page":"e15813","DOI":"10.1371\/journal.pone.0015813","volume":"6","author":"KS Burgdorf","year":"2011","unstructured":"Burgdorf KS, Grarup N, Justesen JM, Harder MN, Witte DR, J\u00f8rgensen T, Sandb\u00e6k A, Lauritzen T, Madsbad S, Hansen T, DIAGRAM Consortium, Pedersen O (2011) Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. PLoS One 6:e15813","journal-title":"PLoS One"},{"key":"2035_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1134\/S0026893307060052","volume":"41","author":"EV Spitsina","year":"2007","unstructured":"Spitsina EV, Yakunina NY, Chudakova DA, Nikitin AG, Svetlova GN, Soluyanova TN, Strokov IA, Nosikov VV (2007) The association of the TP53 polymorphisms Pro72Arg and C(\u2212594)CC with diabetic polyneuropathy in Russian Muscovites with type 1 diabetes mellitus. Mol Biol 41:901\u2013905","journal-title":"Mol Biol"},{"key":"2035_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1515\/jpem.2011.058","volume":"24","author":"ML Bitti","year":"2011","unstructured":"Bitti ML, Saccucci P, Capasso F, Piccinini S, Angelini F, Rapini N, Porcari M, Arcano S, Petrelli A, Del Duca E, Bottini E, Gloria-Bottini F (2011) Genotypes of p53 codon 72 correlate with age at onset of type 1 diabetes in a sex-specific manner. J Pediatr Endocrinol Metab 24:437\u2013439","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2035_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/1753-0407.12250","volume":"7","author":"F Gloria-Bottini","year":"2015","unstructured":"Gloria-Bottini F, Bottini E (2015) Genetic factors adaptive in a malarial environment may increase the risk of type 1 diabetes. J Diabetes 7:430\u2013432","journal-title":"J Diabetes"},{"key":"2035_CR23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ajhg.2009.03.009","volume":"84","author":"H Shi","year":"2009","unstructured":"Shi H, Tan S-J, Zhong H, Hu W, Levine A, Xiao C-J, Peng Y, Qi X-B, Shou W-H, Ma R-LZ, Li Y, Su B, Lu X (2009) Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet 84:534\u2013541","journal-title":"Am J Hum Genet"},{"key":"2035_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri.2016.99","volume":"16","author":"C Mu\u00f1oz-Fontela","year":"2016","unstructured":"Mu\u00f1oz-Fontela C, Mandinova A, Aaronson SA, Lee SW (2016) Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol 16:741\u2013750","journal-title":"Nat Rev Immunol"},{"key":"2035_CR25","doi-asserted-by":"publisher","first-page":"7605","DOI":"10.1073\/pnas.88.17.7605","volume":"88","author":"U Santhanam","year":"1991","unstructured":"Santhanam U, Ray A, Sehgal PB (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A 88:7605\u20137609","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2035_CR26","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1096\/fj.04-3213fje","volume":"19","author":"EA Komarova","year":"2005","unstructured":"Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, Kuprash DV, Nedospasov SA, Hazen SL, Feinstein E, Gudkov AV (2005) p53 is a suppressor of inflammatory response in mice. FASEB J 19:1030\u20131032","journal-title":"FASEB J"},{"key":"2035_CR27","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.4049\/jimmunol.1300509","volume":"191","author":"H Kawashima","year":"2013","unstructured":"Kawashima H, Takatori H, Suzuki K, Iwata A, Yokota M, Suto A, Minamino T, Hirose K, Nakajima H (2013) Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells. J Immunol 191:3614\u20133623","journal-title":"J Immunol"},{"key":"2035_CR28","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2337\/diabetes.54.5.1423","volume":"54","author":"S-J Zheng","year":"2005","unstructured":"Zheng S-J, Lamhamedi-Cherradi S-E, Wang P, Xu L, Chen YH (2005) Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 54:1423\u20131428","journal-title":"Diabetes"},{"key":"2035_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3109\/08916939908994068","volume":"31","author":"HM Kuhn","year":"1999","unstructured":"Kuhn HM, Kromminga A, Flammann HT, Frey M, Layer P, Arndt R (1999) p53 autoantibodies in patients with autoimmune diseases: a quantitative approach. Autoimmunity 31:229\u2013235","journal-title":"Autoimmunity"},{"key":"2035_CR30","first-page":"253","volume":"31","author":"E Di Cesare","year":"2001","unstructured":"Di Cesare E, Previti M, Lombardo F, Di Benedetto A, Mazz\u00f9 N, Romano G, De Luca F, Lasco A, Cucinotta D (2001) Serum anti-p53 autoantibodies in patients with type 1 diabetes. Ann Clin Lab Sci 31:253\u2013258 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11508828","journal-title":"Ann Clin Lab Sci"},{"key":"2035_CR31","doi-asserted-by":"publisher","first-page":"e6527","DOI":"10.1371\/journal.pone.0006527","volume":"4","author":"P Jailwala","year":"2009","unstructured":"Jailwala P, Waukau J, Glisic S, Jana S, Ehlenbach S, Hessner M, Alemzadeh R, Matsuyama S, Laud P, Wang X, Ghosh S (2009) Apoptosis of CD4+ CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS One 4:e6527","journal-title":"PLoS One"},{"key":"2035_CR32","doi-asserted-by":"publisher","first-page":"10358","DOI":"10.3748\/wjg.v21.i36.10358","volume":"21","author":"N Volodko","year":"2015","unstructured":"Volodko N, Salla M, Eksteen B, Fedorak RN, Huynh HQ, Baksh S (2015) TP53 codon 72 Arg\/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. World J Gastroenterol 21:10358","journal-title":"World J Gastroenterol"},{"key":"2035_CR33","first-page":"999","volume":"6","author":"MA Safan","year":"2018","unstructured":"Safan MA, Ghanem AA (2018) Association between polymorphisms of XRCC1 and TP53 genes and endometriosis. JAMMR 6:999\u20131007","journal-title":"JAMMR"},{"key":"2035_CR34","first-page":"259","volume":"9","author":"V Omrani-Nava","year":"2018","unstructured":"Omrani-Nava V, Hedayatizadeh-Omran A, Alizadeh-Navaei R, Mokhberi V, Jalalian R, Janbabaei G, Amjadi O, Rahmatpour G, Mozaffari A (2018) TP53 single nucleotide polymorphism (rs1042522) in Iranian patients with coronary artery disease. Biomed Rep 9:259\u2013265","journal-title":"Biomed Rep"},{"key":"2035_CR35","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40618-015-0292-9","volume":"38","author":"RM Ruggeri","year":"2015","unstructured":"Ruggeri RM, Vicchio TM, Giovinazzo S, Certo R, Alibrandi A, Trimarchi F, Benvenga S, Trovato M (2015) TP53 polymorphism may contribute to genetic susceptibility to develop Hashimoto\u2019s thyroiditis. J Endocrinol Investig 38:1175\u20131182","journal-title":"J Endocrinol Investig"},{"key":"2035_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jcla.20249","volume":"22","author":"RH Chen","year":"2008","unstructured":"Chen RH, Chang CT, Wang TY, Huang WL, Tsai CH, Tsai FJ (2008) p53 codon 72 proline\/arginine polymorphism and autoimmune thyroid diseases. J Clin Lab Anal 22:321\u2013326","journal-title":"J Clin Lab Anal"},{"key":"2035_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1530\/EJE-16-0737","volume":"176","author":"RM Ruggeri","year":"2017","unstructured":"Ruggeri RM, Trimarchi F, Giuffrida G, Certo R, Cama E, Campenn\u00ec A, Alibrandi A, De Luca F, Wasniewska M (2017) Autoimmune comorbidities in Hashimoto\u2019s thyroiditis: different patterns of association in adulthood and childhood\/adolescence. Eur J Endocrinol 176:133\u2013141","journal-title":"Eur J Endocrinol"},{"key":"2035_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.cmet.2013.06.019","volume":"18","author":"CR Berkers","year":"2013","unstructured":"Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH (2013) Metabolic regulation by p53 family members. Cell Metab 18:617\u2013633","journal-title":"Cell Metab"},{"key":"2035_CR39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00592-012-0450-x","volume":"50","author":"AR Bonfigli","year":"2013","unstructured":"Bonfigli AR, Sirolla C, Testa R, Cucchi M, Spazzafumo L, Salvioli S, Ceriello A, Olivieri F, Festa R, Procopio AD, Brandoni G, Boemi M, Marra M, Franceschi C (2013) The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study. Acta Diabetol 50:429\u2013436","journal-title":"Acta Diabetol"},{"key":"2035_CR40","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.4161\/cc.10.9.15344","volume":"10","author":"GA Azzam","year":"2011","unstructured":"Azzam GA, Frank AK, Hollstein M, Murphy ME (2011) Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle 10:1352\u20131355","journal-title":"Cell Cycle"},{"key":"2035_CR41","doi-asserted-by":"publisher","first-page":"e0228296","DOI":"10.1371\/journal.pone.0228296","volume":"15","author":"M Pellegrino","year":"2020","unstructured":"Pellegrino M, Traversi G, Arena A, Cappa M, Rosado MM, Andreani M, Delfino DV, Moretti F, Fierabracci A (2020) Effect of p53 activation through targeting MDM2\/MDM4 heterodimer on T regulatory and effector cells in the peripheral blood of Type 1 diabetes patients. PLoS One 15:e0228296","journal-title":"PLoS One"},{"key":"2035_CR42","first-page":"a001032","volume":"2","author":"LF Grochola","year":"2020","unstructured":"Grochola LF, Zeron-Medina J, M\u00e9riaux S, Bond GL (2020) Single-nucleotide Polymorphisms in the p53 Signaling Pathway. Cold Spring Harb Perspect Biol 2:a001032","journal-title":"Cold Spring Harb Perspect Biol"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-02035-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-020-02035-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-02035-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T10:14:19Z","timestamp":1674900859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-020-02035-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2035"],"URL":"https:\/\/doi.org\/10.1007\/s00109-020-02035-1","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"11 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Medical University of Gda\u0144sk (NKEBN\/2014\/2009; 2009).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}